All posts tagged ross camidge

  • Camidge.Slider.940x530

    Promising trial results of brigatinib show that all next-gen ALK inhibitors may not be created equal

    Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

Economics influence cancer treatment decisions. But are the numbers as solid as they seem? Image: Flickr/Simon Cunningham cc license.
Ross Camidge, MD, chief of the Lung Cancer program at
the University of Colorado Cancer Center, helped to enroll Rabinowitz
in the phase 1 trial of a new ALK inhibitor.
Ross Camidge, MD, PhD